Dr. Tolaney Discusses Patient Selection for Platinum-Based Therapy in TNBC
Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).
Tolaney believes the standard of care will remain standard chemotherapy for triple-negative disease. However, she feels it is important to learn which patients could benefit from the additional platinum-based therapy.
A common question is whether or not a patient with aBRCAmutation should receive platinum-based therapy. In previous studies, the pathological complete response rates were high for patients with this mutation, so it may be beneficial for this therapy to be incorporated intoBCRAcarriers in the future.
Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
